SPONSORED CONTENT
Pop Quiz: Which of these statements are false?
Arkansas’s first-of-its-kind law requiring drug makers to honor 340B pricing when covered entities use contract pharmacies to dispense 340B drugs is not preempted by the federal 340B statute since the state law applies only to the acquisition and
…
SPONSORED CONTENT
At AllianceRx Walgreens Pharmacy, each covered entity we meet with describes circumstances unique to its hospital, patients, and pharmacy arrangements. The common element for all is the increasing complexity of 340B programming – often changing by the day. Other themes we often hear about include variable patient volumes, unpredictable cost trends and operational
…
The National Association of Community Health Centers “would love to see” Congress pass legislation by the end of this year that stops drug makers from restricting 340B contract pharmacy arrangements and stops pharmacy benefit managers from taking covered
…
Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
In a major blow to the 340B provider community, U.S. Rep. David McKinley, the leading voice for the 340B program in the House Republican caucus, was defeated Tuesday in the West Virginia Republican primary. McKinley will remain in
…
Six groups that support patients with HIV/AIDS and viral hepatitis and their caregivers issued a joint statement yesterday criticizing drug manufacturers AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.
At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.
Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.
…
Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.
…*Sign up for news summaries and alerts from 340B Report
